WO2003051380A2 - Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders - Google Patents
Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders Download PDFInfo
- Publication number
- WO2003051380A2 WO2003051380A2 PCT/IB2002/005366 IB0205366W WO03051380A2 WO 2003051380 A2 WO2003051380 A2 WO 2003051380A2 IB 0205366 W IB0205366 W IB 0205366W WO 03051380 A2 WO03051380 A2 WO 03051380A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- fraction
- another embodiment
- present
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the method of producing lipid soluble extract called Curcuma oil in high yield, from rhizomes and leaves of species of zingiberaceae family, particularly Curcuma species and also use of the said oil, its constituents, and novel derivatives of said constituents, for the treatment of Neurocerebrovascular disorders
- Neurocerebrovascular diseases like cerebrovascular infarction, stroke, ischemic attacks etc. are caused by an interruption of the blood supply resulting from disease of the arteries carrying blood to the brain.
- cerebral hemorrhage is caused by rupture of a blood vessel with bleeding into the brain (intra cerebral hemorrhage) or under its covering membrane, while cerebral thrombosis stems from obstruction of a cerebral blood vessel when a blood clot forms within the walls.
- the clot may be caused by abnormal thickening of the blood, damage to the vessel wall from arteriosclerosis, atherosclerosis, inflammation of the arteries or inflammation of the veins.
- Cerebral embolism is obstruction of a cerebral artery by a blood clot or a foreign body migrating from another part of the body's circulation like when a clot that has formed on the inside wall of one of the arteries in the neck travels up to the brain and blocks a major artery branch.
- TIAs Trasient ischemic attacks
- RJNDs Reversible ischemic neurological def ⁇ cits
- RJNDs small cerebral infarction. Multiple cerebral infarction can lead to permanent confusion and memory loss.
- Ischemic stroke is a medical emergency. After TIAs or stroke occur, treatment may be surgical or medical. Surgery may be needed in some cases to remove any blockage of blood vessels going to the brain.
- Medication can prevent the formation of blood clots on the atheroscl-erotic plaques within the vessel wall. Brain swelling commonly accompanies brain infarction or hemorrhage.No satisfactory treatment is available.
- peripheral vascular and cerebral disorders include ergot alkaloids, aspirin, anti-coagulants etc.
- aspirin aspirin
- anti-coagulants etc.
- the latter are used following strokes to prevent further cerebrovascular incidents but their use is contraindicated if the stroke was the result of hemorrhage.
- Tissue plasminogen activator used to treat clots in the coronary arteries (acute heart attack), is a natural clot dissolving substance produced by the body which can blow open a blood clot in the brain that causes the acute ischemic brain damage characteristic of a stroke.
- t-PA can dissolve the blood clot that causes a blood vessel blockage, there are other complications which occur during ischemic stroke which must be addressed if permanent brain damage is to be prevented.
- NO nitric oxide
- superoxide scavengers in the blood stream when t-PA is administered to reduce the free radical damage that will occur when the blood flow is restricted and even more when the flow is resumed.
- Brain cells die as a result of the actions: calcium activated proteases (enzymes which digest cell proteins),lipases(enzymes which digest cell membranes) and free radicals formed as a result of the ischemic cascade.
- nerve cells may be irreversibly damaged within several minutes. Any disruption of blood flow to the brain causes massive free radical damage that induces much of the re-perfusion injury to brain cells, typical of strokes.
- tissues release iron that acts as a catalyst for the formation of free radicals that often permanently damage brain cells.
- Ayurvedic drugs are products of high repute which act on a number of dysfunctions of the body involving various organs and aim at preventing problems or restoring a normal situation, and try to recover the patient completely. Evolved over a long period of time and experimentation, they are the results of a particular combination of certain fundamental elements which determine their properties which in turn are responsible for the chemical, biological or therapeutic effects of those substances. There is no substance when correctly prepared which can not be used as remedy.
- Ayurveda describes a number of beneficial effects of rhizomes and leaves of various species belonging to zingiberaceae family, especially those of Curcuma longa .syn.Curcuma domestica Naleton, rhizomes and leaves popularly known as Turmeric or Haldi. Prominent among these are the anti-bacterial, antifungal wound healing and the anti-inflammatory actions which enabled turmeric paste to be used as a house hold remedy to treat wounds and inflammation.
- Curcumin A major constituent Curcumin was developed as an anti-inflammatory agent [Srimal R.C.,Khanna ⁇ .M.,Dhawan B.N., Ind. J. Pharmacol.,3, 10 (1971)].
- Other therapeutic properties of Curcumin, various curcuminoids and some other constituents of Curcuma species include anti-bacterial, anti-fungal [Schraufstatter F., Brent H., Nature, 164,456(1949), Arch.Dermatol..u.Syphilis,iS ⁇ °,250 (1949);Lutomski.J.,KedziaB.,Debska W,Planta Med., 26, 9 (1974 ) ; Rao B.G.N., Joseph P., Reichst,Aromen Koerperflegem, 2/,405-406(1971); Swada T., Hyundaira J., Shimazu S., Ohta T., Shoyakugaku Zasshi, 2 ,11-16(19
- Ethyl p-methoxy cinnamate isolated from Curcuma rhizomes essential oil exhibit antifungal activity[ Herba Hung., 28, 95(1989), via Chem. Abstr. Ill, 191496J (1989)], while furanogermenone and (4S,5S) (+) germacrone 4,5-epoxide also isolated from Curcuma rhizomes essential oil exhibits anti-inflammatory and preventive effect against stress ulceration [Yakugaku Zasshi, 106, 1137 (1986),Chem. Abstr..106, 95935c (1987); Zhongyao Tungbto, 10, 134 (1983),Chem. Abstr. 103, 115886d(1985)].
- the main object of the present invention is to use the lipid soluble extract from rhizomes and leaves of Curcuma species, which belong to zingiberaceae family for the treatment of Neurocerebrovascular disorder.
- Another object of the present invention is to develop a method to produce lipid soluble extract in high yield from rhizomes and leaves of Curcuma species, which belong to zingiberaceae family.
- Yet another object of the present invention is to separate individual components from the Curcuma oil.
- Still another object of the present invention is to develop analogs of the said constituents of the Curcuma oil.
- Still another object of the present invention is to detect the Neurocerebrovascular disorders of the said analogs.
- Still another object of the present invention is to identify active components in Curcuma species for the treatment of neurocerebrovascular disorders.
- Still another object of the present invention is to use active components of Curcuma species for the treatment of ischemia.
- Still another object of the present invention is to use active components of Curcuma species for the treatment of stroke.
- Still another object of the present invention is to use active components of Curcuma species for the treatment of hemorrhage.
- Still another object of the present invention is to use active components of Curcuma species for the treatment of thrombosis. Summary of the present invention
- the present invention relates to the method of producing lipid soluble extract called Curcuma oil in high yield.
- the source of said oil is rhizomes and leaves of species of zingiberaceae family.
- the particularly species of the said family used to produce said oil is Curcuma species.
- the said oil is used for the treatment of Neurocerebrovascular disorders.
- the novel analogs of the constituents of said oil are developed and are also found to have use in the treatment of Neurocerebrovascular disorder.
- the present invention relates to an improved method of obtaining high yields of the lipid soluble extract called Curcuma oil and its constituents from rhizomes and leaves of species of Zingiberaceae family particularly Curcuma species.
- composition obtained from the lipid soluble extract of rhizomes and leaves of Curcuma species of Zingiberaceae family, useful for the treatment of neurocerebrovascular disorders comprising fraction A consisting of ar-turmerone of formula 1, and turmerone of formula 2, and/or along with fraction B consisting of curcumene and zingiberine, and/or fraction C consisting of germacrone, curcumerone, zedoarone, sedoarondiol, isozdedoaronidiol, curcumenone, and curlone, and/or pharmaceutically acceptable additives.
- curcuma species is Curcuma domestica Valeton.
- ratio of fraction A, fraction B, and fraction C is ranging between 1 to 3: 1 to3: lto 3.
- additives are selected from a group comprising melatonin, antioxidants, calcium channel antagonists, tissue plasminogen activator (t-PA), and cell membrane stabilizing agents.
- said composition inhibits nitric oxide synthase (NOS) overproduction, prevention calcium overload in neurons, and scavenging free radicals.
- NOS nitric oxide synthase
- composition cerebrovascular disorders are selected from a group comprising ischaemia, stroke, post- stroke injury, hemorrhage, reperfusion injury, thrombosis, vasoconstriction, nitric oxide- induced free radical oxidative damage, infraction, inflammation, and Alzheimer's disease.
- polar solvent is selected from a group comprising alcohol and acetone.
- non-polar solvent is selected from a group comprising light petroleum and toluene.
- fraction A constitutes about 75% of the said extract.
- pressure is ranging between 7 and 11 mmHg.
- concentration of the extract is about 6%.
- a method of treating neurocerebrovascular disorders in animals including humans using composition of claim 1, by administering therapeutically effective amount of lipid soluble extract by administering therapeutically effective amount of lipid soluble extract.
- NOS nitric oxide synthase
- cerebrovascular disorders are selected from a group comprising ischaemia, stroke, post-stroke injury, hemorrhage, reperfusion injury, thrombosis, vasoconstriction, nitric oxide-induced free radical oxidative damage, infraction, inflammation, and Alzheimer's disease.
- a method of treating Ischaemia in animals including humans using composition of claim 1 comprises step of administering therapeutically effective amount to the subject.
- the effective amount is ranging between 10-1000 mg/day in divide dosage schedule.
- composition is administered through various routes comprising i.p., and p.o.
- method prevents overload of calcium ions in the mitochondria.
- a method of treating stroke in animals including humans using composition of claim 1 comprises step of administering therapeutically effective amount to the subject.
- the effective amount is ranging between 10- In still another embodiment of the present invention, 1000 mg/day in divide dosage schedule.
- composition is administered through various routes comprising i.p., and p.o.
- a method of treating hemorrhage in animals including humans using composition of claim 1 comprises step of administering therapeutically effective amount to the subject.
- the effective amount is ranging between 10-500 mg/day in divide dosage schedule.
- composition wherein the said composition is administered through various routes comprising i.p., and p.o.
- fraction A is most effective.
- a method of treating thrombosis in animals including humans using composition of claim 1 comprises step of administering therapeutically effective amount to the subject.
- thrombosis is selected from a group comprising cerebral, coronary, and deep vein.
- the effective amount is ranging between 10-1000 mg/day in divide dosage schedule.
- composition is administered through various routes comprising i.p., and p.o.
- a method of treating hypertension in animals including humans using composition of claim 1, said method comprises step of administering therapeutically effective amount to the subject.
- the effective amount is ranging between 10-1000 mg/day in divide dosage schedule.
- composition is administered through various routes comprising i.p., and p.o.
- a method of treating vasoconstriction in animals including humans using composition of claim 1 comprises step of administering therapeutically effective amount to the subject.
- the effective amount is ranging between 10-1000 mg/day in divide dosage schedule.
- composition is administered through various routes comprising i.p., and p.o.
- said method comprises step of administering therapeutically effective amount to the subject.
- the effective amount is ranging between 10-1000 mg/day in divide dosage schedule.
- composition wherein the said composition is administered through various routes comprising i.p., and p.o.
- fraction A is most effective.
- animals including humans using composition of claim 1, said method comprises step of administering therapeutically effective amount to the subject.
- said method involves treating various kinds of edema selected from a group comprising brain and pulmonary edema.
- the effective amount is ranging between 10-1000 mg/day in divide dosage schedule.
- composition is administered through various routes comprising i.p., and p.o.
- Curcuma species is selected from a group comprising Curcuma longa L.Syn. Curcuma domestica Naleton, and Curcuma aromatica Salisb.
- the organic solvent is non- polar organic solvent selected from a group comprising light petroleum, and toluene.
- the organic solvent is polar organic solvent selected from a group comprising ethanol, and propanol.
- non-polar organic solvents give higher yield as compared to polar organic solvents.
- the residual concentrate from polar organic solvent extract is extracted with non-polar organic solvent.
- Curcuma oil is separated into its individual constituents comprising ar-d-turmerone (formula 1), turmerones of ⁇ and ⁇ (formula 2), zingiberine, curcumene, germacrone, curcumenone, and curlone.
- kind of the Chromatography is selected from a group comprising Column Chromatography preferably High Performance Liquid Chromatography, and Gas- Liquid Chromatography.
- the adsorbent for the Chromatography is selected from a group comprising alumina, and silica gel.
- the elution of the said constituents is with organic solvent selected from a group comprising n-hexane, ethyl acetate, and n- hexane and ethyl acetate mixture in varying proportions.
- molecular weight of the individual constituents of Curcuma oil separated by chromatography is turmerones ( ⁇ -, ⁇ -) - mol.wt. 218, ar-d-turmerone - mol.wt.216, zingiberine -mol.wt.204, and Curcumene -mol.wt.202.
- retention time of the individual constituents of Curcuma oil separated by chromatography is turmerones ( ⁇ -, ⁇ -) - retention time 9' -04", ar-d-turmerone - retention time 8'-08", zingiberine - retention time 5'-04", and Curcumene - retention time 4'-24".
- Novel compound of the formula 3 an analog of compounds comprising ar-d-turmerone, turmerone, and germacrone wherein, R represents an alkyl, alkenyl, cycloalkane, phenyl, cycloalkene, or cycloalkadiene group, with substituents like alkyl, or alkoxy halo, in the phenyl, cycloalkene, cycloalkadiene rings, or hetroaryl like pyridyl nitrogen heterocyclic amine and substituted amines, and RI represents alkyl or arylalkyl group.
- Novel Compound of the formula 4 an analog of compounds comprising Procurcumenol, zedoarondiol, and curcumenone.
- composition useful for treatment of Neurocerebrovascular disorders comprising effective amount of the lipid soluble extract called Curcuma oil, from rhizomes and leaves of species of plant Zingiberaceae family particularly Curcuma species, either as such or its individual constituents singly or in combination with each other or related compounds comprising melatonin, and tissue plasminogen activatior (t-PA), optionally associated with pharmaceutically acceptable additives.
- Curcuma oil lipid soluble extract
- Curcuma oil from rhizomes and leaves of species of plant Zingiberaceae family particularly Curcuma species, either as such or its individual constituents singly or in combination with each other or related compounds comprising melatonin, and tissue plasminogen activatior (t-PA), optionally associated with pharmaceutically acceptable additives.
- t-PA tissue plasminogen activatior
- NO nitric oxide
- the additive is selected from a group of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste, ' and/or pharmaceutically acceptable carrier, excipient, diluent, or solvent.
- composition for the oral route is administered orally, inhaled, or implanted.
- physical state of the said composition for the oral route is in the form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, or beads.
- In still another embodiment of the present invention is administered at dosage level ranging between 5 to 5000 mg/day.
- h still another embodiment of the present invention is used for treating hypertension.
- In still another embodiment of the present invention is used for treating cerebrovascular diseases comprising strokes, and transient ischaemic attacks.
- thrombosis infraction comprising cerebral, coronary, and deep vein.
- In still another embodiment of the present invention is used for treating Alzheimer's disease wounds. In still another embodiment of the present invention is used for treating Acquired Immunodeficiency Syndrome.
- a method of treating a subject for Neurocerebrovascular disorder conditions comprising administering to the subject effective amount of the lipid soluble extract called Curcuma oil, from rhizomes and leaves of species of plant Zingiberaceae family particularly Curcuma species, either as such or its individual constituents singly or in combination with each other or related compounds comprising melatonin, and tissue plasminogen activatior (t- PA), optionally associated with pharmaceutically acceptable additives.
- the additive is selected from a group of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste, and/or pharmaceutically acceptable carrier, excipient, diluent or solvent.
- composition is administered orally, inhaled, or implanted.
- the physical state of said composition for the oral route is in the form of capsule, tablet, syrup, concentrate, powder, granule, aerosol, or beads.
- composition is administered at a dosage level ranging between 5 to 5000 mg/day. In still another embodiment of the present invention the composition is used for treating hypertension.
- composition is used for treating cerebral, and pulmonary edema which accompanies cerebral, and myocardial infarction.
- composition is used for treating post- stroke injury.
- composition is used for treating reperfusion injury.
- composition is used for treating cerebrovascular diseases comprising strokes, and transient ischaemic attacks.
- composition is used for treating all kind of strokes comprising thromotic, embolic, focal, and recurrent.
- composition is used for treating subarachnoid, and cerebral hemorrhage.
- composition is used for treating neurological dysfunction.
- composition is used for treating thrombosis infraction comprising cerebral, coronary, and deep vein.
- composition is used for treating cancer.
- composition is used for treating Alzheimer's disease wounds
- composition is used for treating Acquired Immunodeficiency Syndrome. In still another embodiment of the present invention the composition is used for treating migraine.
- composition is administered again in case of relapse conditions.
- obtain/prepare -therapeutically effective medicaments from extracts of Curcuma species rhizomes and leaves which belong to Zingiberaceae family.
- the lipid soluble extract/fraction of Curcuma longa L. syn. Curcuma domestica Naleton commonly known as turmeric or Haldi .
- formulations / delivery systems such as tablets, capsules, suppository, beads, aerosols, etc. for the treatment and prevention of human diseases in which increased production of Nitric Oxide (NO) and free radical oxidative damage are implicated.
- NO Nitric Oxide
- such diseases are neurocerebrovascular disorders like transient ischaemic attacks (ischaemic, hemorrhagic, focal recurrent etc.) thrombosis (cerebral, coronary ,deep vein), infarction, stroke (thrombotic, embolic, focal etc.), Alzheimer's disease, inflammat-ory, neurological dysfunctions, wounds , carcino genesis, tumor progression etc.
- transient ischaemic attacks ischaemic, hemorrhagic, focal recurrent etc.
- thrombosis cerebral, coronary ,deep vein
- infarction thrombotic, embolic, focal etc.
- Alzheimer's disease inflammat-ory
- neurological dysfunctions wounds
- wounds wounds
- carcino genesis tumor progression etc.
- the superoxide and nitric oxide (NO) scavenging property of the lipid soluble extract / fraction of Curcuma species rhizomes (Family: Zingieraceae) especially Curcuma longa L. Syn. Curcuma domestica Naleton, hereinafter referred to as Curcuma oil either as such or its various constituents singly or in combination with each other which makes them therapeutically effective to control various degenerative diseases, more particularly a drug which is nitric Oxide (NO) and superoxide scavenger with anti-inflammatory activity to combat brain and pulmonary edema / swelling which accompanies brain and myocardial infarction.
- NO nitric Oxide
- Curcuma oil obtained from Curcuma longa L.syn.
- Curcuma domestica Naleton, rhizomes and leaves either as such or its major active constituents, ar-d-turmerone (formula 1), turmerones ( -, ⁇ -,formula 2) either singly or in combination with each other with and with the other minor constituents are found to be significantly beneficial and possess powerful Nitric oxide(NO) and free radical / superoxide scavenging activity.
- said lipid soluble extract exhibit/possess potent free radical scavenging/ antioxidant activity which enables them to protect mitochondrial impairment protecting downstream target and they inhibit ove ⁇ roduction of nitric oxide synthase (NOS), avoid injury due to inflammation and reduce calcium entry so that the resultant calcium overload in the neurons does not occur.
- NOS nitric oxide synthase
- Another important advantage is that if there is any blockage, the above three parameters which are the major cause of reperfusion injury are taken care of by these medicaments and the collaterals from the "Circle of Willis" are able to help in the blood flow and thereby enable the drug to reach the site of injury.
- Curcuma oil either as such or its individual constituents such as ar-d-turmerone, turmerones etc. singly or in combination with each other with and without other related compounds of the type of formula 3 or 4 and /or other therapeutically beneficial agents such as melatonin, other antioxidants, calcium channel antagonists, tissue plasminogen activator (t-PA) and cell membrane stabilizing agents can provide effective protection against cerebral and even coronary damage.
- Curcuma oil either as such or its individual constituents such as ar-d-turmerone, turmerones etc. singly or in combination with each other with and without other related compounds of the type of formula 3 or 4 and /or other therapeutically beneficial agents such as melatonin, other antioxidants, calcium channel antagonists, tissue plasminogen activator (t-PA) and cell membrane stabilizing agents can provide effective protection against cerebral and even coronary damage.
- t-PA tissue plasminogen activator
- the lipid soluble extract of rhizomes and leaves of Curcuma species of the family zingiberaceae especially Curcuma longa L..syn.
- Curcuma domestica Valeton hereinbefore referred to as Curcuma oil which is a pale yellow to orange yellow odoriferous oily liquid whose major constituents are: ar-d-turmerone(formula 1), turmerones ( ⁇ -, ⁇ -, formula 2)[Tap Chi Hoa Hoc:25, 18(1987) ; Chem.Abstr.,705,137682 s (1988)] besides other minor constituents such as zingiberine, curcumene, curlone, curculone, curzenone, ⁇ -, ⁇ - curcumenolides ,curcumenone, curdione,germacrone, linalool ,camphor, borneol, zingiberol etc.
- nitric oxide is a free radical scavenger/ antioxidant which can penetrate the blood brain barrier and provide effective therapeutic protection by combating nitric oxide(NO)and superoxide/free radical induced neuronal injury / damage in human diseases such as neurocerebrovascular dysfunctions, all types of strokes, thrombosis ( cerebral, coronary, deep vein), infarction, inflammatory and neurological disorders ,certain types of cancer, wounds, Alzheimers disease and other nitric oxide neurotoxicity, hyperbaric oxygen exposure etc.
- high yields. of the lipid soluble material is obtained from Curcuma species rhizomes and leaves (Family: Zingiberaceae), particularly Curcuma longa L. syn. Curcuma domestica Valeton, hereinafter referred to as Curcuma oil and isolation of its various constituents.
- this invention relates to nitric oxide (NO) and superoxide scavenging activity and prevention of any changes in cerebral blood flow dynamics by Curcuma oil itself or by its constituents singly or in combination with one another which enables their use as medicaments for the treatment and prevention of neurocerebrovascular disorders and related and unrelated dysfunctions such as ischemic attacks, all types of stroke, thrombosis, infarction, migraine, Alzheimer's disease, inflammatory and neurological dysfunctions, carcinogensis, tumor progression wounds and even HIV/AIDS.
- NO nitric oxide
- Curcuma oil itself or by its constituents singly or in combination with one another which enables their use as medicaments for the treatment and prevention of neurocerebrovascular disorders and related and unrelated dysfunctions such as ischemic attacks, all types of stroke, thrombosis, infarction, migraine, Alzheimer's disease, inflammatory and neurological dysfunctions, carcinogensis, tumor progression wounds and even HIV/AIDS.
- Novel compound of the formula 3 an analog of compounds comprising ar-d-turmerone, turmerone, and germacrone wherein, R represents an alkyl, alkenyl, cycloalkane, phenyl, cycloalkene, or cycloalkadiene group, with substituents like alkyl, or alkoxy halo, in the phenyl, cycloalkene, cycloalkadiene rings, or hetroaryl like pyridyl nitrogen heterocyclic
- RI represents alkyl or arylalkyl group.
- Novel Compound of the formula 4 an analog of compounds comprising Procurcumenol, zedoarondiol, and curcumenone.
- Fig.l shows prevention of infarction from focal ischaemic rat after using curcuma oil
- Fig.2 shows past occlusion complete prevention of infarction in forebrain after using fraction
- Fig.3 shows past occlusion complete prevention of infarction in forebrain after using fraction
- Fig.4 shows Calcium transients in mitochondria (340/380 ratio);
- Fig.5 shows change in SOD levels in mitochondria after using fraction A and fraction B;
- Fig.6 shows Catalase levels in mitochondria after using fraction A and fraction B
- Fig.7 shows Malondialdehyde levels in mitochondria after using fraction A
- Fig.8 shows change in percent relaxation to NE induced contraction
- Fig.9 shows change in SNP levels in mitochondria after using fraction A.
- the present invention provides a method of obtaining the lipid soluble extract / fraction of rhizomes and leaves of various species belonging to zingiberaceae family, especially Curcuma oil from Curcuma- species in good yield by extraction of powdered rhizomes / leaves of Curcuma longa L.
- the residual alcoholic concentrate after removal of the solvent is exhaustively extracted with a non-polar organic solvent like light-petroleum, toluene etc.
- distillation of solvent from such extracts under reduced pressure below 45° C yields a pale yellow to orange yellow odoriferous liquid in 5 to 6 per cent yields.
- fractionation of this oil by column chromatography over a suitable adsorbent and elution by an appropriate organic solvent or by HPLC or GLC or distillation in vacuum yields the individual constituents such as ar-d- turmerone (formula 1), turmerones ( ⁇ -, ⁇ -, formula 2) as major constituents (about 70 percent as determined by GC-MS) besides other minor constituents like zingiberine, curcumene, zedeorone, germacrone, curlone, curdione etc. all identified by GC-MS etc.
- an improved method of obtaining the lipid soluble extract / material of rhizomes and leaves of various species of Zingiberaceae family especially Curcuma species such as Curcuma longa L.Syn. Curcuma domestica Valeton or Curcuma aromatica Salisb. etc. in high yields by exhaustive extraction of finely powdered rhizomes or leaves with an appropriate organic solvent under continous gradual stirring or by sonication at ordinary room temperature followed by removal of the solvent from the extract by distillation under reduced pressure below 45 ° C.
- the organic solvent is a non- polar organic solvent such as light petroleum, toluene etc.
- the organic solvent used is a polar organic solvent such as ethanol, propanol etc.
- the residual concentrate after removal of the solvent from the polar organic solvent extract is exhaustively extracted with a non-polar organic solvent such as light- petroleum, toluene etc.
- the organic solvent is removed from the extracts by distillation under reduced pressure below 45 ° C.
- the continuos' stirring is done either manually or by a mechanical stirrer or by an electric motor.
- the lipid soluble extract /material of rhizomes or leaves of said species which, is a pale yellow to orange-yellow odoriferous oily liquid, is separated into its individual constituents such as ar-d-turmerone (formula 1), turmerones ( ⁇ , ⁇ -formula 2), zingiberine, curcumene, germacrone, curcumenone, curlone etc. by chromatography (column, HPLC, GLC etc.) or distillation under high vacuum.
- the individual constituents of the Curcuma oil are obtained by column chromatography over a suitable adsorbent such as alumina, silica gel etc. and elution by appropriate organic solvents such as n-hexane, njhexane : ethyl acetate mixture (in varying proportions), ethyl acetate etc..
- a suitable adsorbent such as alumina, silica gel etc.
- organic solvents such as n-hexane, njhexane : ethyl acetate mixture (in varying proportions), ethyl acetate etc.
- the individual constituents of Curcuma oil are obtained by HPLC or GLC, e.g. turmerones ( ⁇ -, ⁇ -), mol.wt. 218, retention time 9' -04", ar-d-turmerone (mol.wt.216), retention time 8'-08", zingiberine (mol.wt.204) retention time 5'-04", Curcumene (mol.wt.202),. retention time 4'-24".
- the individual constituents of Curcuma oil such as ar-d-turmerone(formula 1), turmerones(formula 2), zinziberine, curcumene, curcumenone, germacrone etc.
- Curcuma oil in vacuum, e.g. ar- d-turmerone, b.p. 155-160 °C / 9mm Hg through ar-d-turmerone rich fraction ,b.p. 140-160 ° C /10mm Hg which is about 70 % of the whole Curcuma oil
- fig.l ar-d- turmerone
- fig.2 termerones
- gennacrone gennacrone
- curcumenone zingiberine
- curcu-meneetc either as such or it individual constituents.
- R represents an alkyl, alkenyl, cycloalkane, phenyl, cycloalk-ene or cycloalkadiene with substituents like alkyl
- compounds of the type- formula 4 as analogs of Procurcumenol, zedoarondiol, curcum-enone etc. -the other minor constituents of the lipid soluble extract of the Curcuma species which incorporate in their molecular architecture the salient features of ar-d-turmerone and turmerone( ⁇ -, ⁇ -) molecules in a rigid frame work as therapeutically beneficial medicaments for the treatment and prevention of all types of stroke, thrombosis, infarction , neurological dysfunctions etc.
- therapeutically beneficial effects of Curcuma oil as such or its individual constituents singly or in combination with each other or of related compounds reduce, control or prevent human diseases in which increased production of nitric oxide (NO) and free radical oxidative damage to important biomolecules is implicated such as all types of stroke (thrombotic, embolic, focal, ischaemic), thrombosis (cerebral, coronary, deep vein) infarction, neurological dysfunctions etc.
- NO nitric oxide
- free radical oxidative damage to important biomolecules is implicated such as all types of stroke (thrombotic, embolic, focal, ischaemic), thrombosis (cerebral, coronary, deep vein) infarction, neurological dysfunctions etc.
- method of treating post-stroke injury in mammals which comprises administering to a subject in need thereof an effective amount of Curcuma oil either as such or its individual constituents singly or in combination with each other or related compounds.
- method of treating patients of Subarachnoid and cerebral hemorrhagic stroke after 5 to 7 hours of the stroke by administering to a subject in need thereof a therapeutically effective amount of Curcuma oil either as such (whole) or its individual constituents singly or in combination with each other or related compounds.
- method of treating reperfusion injury in mammals that comprises administering to a subject in need thereof an effective amount of Curcuma oil (whole-as such) or its individual constituents singly or in combination with each other or related compounds.
- method of treating cerebrovascular diseases like all types of stroke thrombotic, embolic, focal, recurrent
- transient ischaemic attacks etc. by administering to a subject in need thereof an effective amount of Curcuma oil (whole-as such) or its individual constituents singly or in combination with each other or related compounds.
- method of treating ischaemic diseases and prevent dangerous blood clot formation by administering to a subject in need thereof an effective amount of Curcuma oil (whole) or its individual constituents singly or in combination with each other or related compounds.
- method for treating hypertension in mammals comprises administering to a subject/ patient in need thereof an effective amount of Curcuma oil (whole) or its individual constituents singly or in combination with each other or related compounds.
- method to combat cerebral and pulmonary edema which accompanies cerebral and myocardial infarction by administering to a subject in need thereof medicaments like Curcuma oil (whole) or its individual constituents singly or in combination with each other or related compounds, which are nitric oxide (NO) and superoxide/free radicals scavengers with anti-inflammatory activity.
- medicaments like Curcuma oil (whole) or its individual constituents singly or in combination with each other or related compounds, which are nitric oxide (NO) and superoxide/free radicals scavengers with anti-inflammatory activity.
- therapeutically beneficial effects of the SAID lipid soluble extracts either as such or its individual constituents like ar-d-turmerone, turmerones, germacrone, zinziberine, curcumene, curlone etc.
- melatonin tissue plasminogen activator (t-PA) administered orally, parentally (individual pure constituents) or in any other appropriate pharmaceutically acceptable delivery system such as tablets, capsules, beads, suppositories aerosols, implants etc in an effective amount (for Stroke, 10 - 500 mg / daily in divided doses and for other Ailments, 10 -1000 mg/ daily in divided doses),to provide a highly effective cure/treatment for human diseases wherein nitric oxide (NO) and free radical oxidative damage are implicated such as all type of stroke, thrombosis, infarction and neurological dysfunctions and which may also be of therapeutic use in certain type of cancer such as leukemia, Alzheimer's disease wounds and even HIV./ AIDS.
- NO nitric oxide
- free radical oxidative damage are implicated such as all type of stroke, thrombosis, infarction and neurological dysfunctions and which may also be of therapeutic use in certain type of cancer such as leukemia, Alzheimer's disease wounds and even HIV
- This example describes the method of obtaining Curcuma oil and its constituents in high yields and preparation of its dosage formulations. Improved extraction procedure of Curcuma oil and its constituents from Curcuma longs L. syn. Curcuma domestica Valeton or other Curcuma species rhizomes.
- the usual extractive procedure employs three or four percolations of dry powdered Curcuma rhizomes with an organic solvent like light petroleum, toluene, alcohol etc. and distillation of the solvent from the percolates.
- an organic solvent like light petroleum, toluene, alcohol etc.
- distillation of the solvent from the percolates In case of alcoholic extracts, after solvent removal the residual concentrate is triturated with a non-polar organic solvent like light petroleum followed by removal of the solvent by distillation to yield Curcuma oil in 1 to 1.5 percent yields.
- the solid dosage form may be obtained by maceration of Curcuma oil as such or its individual constituents singly or in combination with each other particularly ar-d-turmerone, ⁇ -, ⁇ - turmerones with starch and microcrystalline cellulose in suitable proportions in a mixer till the mixture becomes a free flowable powder which may be filled in capsules or converted into tablets as per therapeutically desired specifications.
- Curcuma oil (10.0 gm.) was dissolved in ethanol (100ml). Starch (5.0gm) and microcrystalline cellulose (85.0 gm) were added to this solution. The contents were mixed thoroughly and solvent was removed by drying below 45°C. The resulting product was passed through 40-mesh size sieve to obtain free flowing granules. These granules were then compressed into tablets of appropriate dosage requirements, e.g. each tablet weighing 500mg.contain 50mg of Curcuma oil.
- Rats Male Sprague Dawley rats of 270-375 gm weight from CDRI Animal House were used for this study. Rats were housed in a 12-hr. light / dark cycle and water was given ad libitum. Animals were fasted overnight and anaesthetized with pentobarbitone sodium, 30mg/kg. Rectal temperature was monitored.
- Mitochondria were isolated from the rat forebrain according to the method of Lai and Clark [Lai J.C.K., Clark J.P., Preparation of synaptic and non-synaptic mitochondria from mammalian brain: Method EnzymoL, 55, 51-60(1979)] with slight modifications.
- Rat forebrain was immediately removed after decapitation and immersed in ice- cold isolation medium or Phosphate Buffered Saline. Brains were minced and rinsed to remove all the traces of blood. The tissue was homogenized (10% w/v) in an appropriate medium using a motorized Teflon homogenizer and immediately centrifuged at 1800g for 10 min.
- the supernatant was decanted and the pellet rehomogenized and centrifuged at 1800 g for 10 min. Supernatants from the first and the second spins were added together and centrifuged at 17,000 g for 20 minutes. The resultant pellet was resuspended in specific mediums and centrifuged at 17000 g. for 5 minutes.
- the ratio of Fura-2 fluorescence at exciting wavelength of 340 and 380 nm with emission at 510 nm was determined using a Shimadzu RF 5000 Spectrofluorometer. Mitochondrial Calcium([Ca 2+ ] m ), is presented as tracings of the 340/380 fluorescence ratio[Macleod K.T
- Rats Female male rats (250-350 gm.) from the CDRI- Animal House were used in the following experiments. The rats were anaesthetized with pentobarbitone sodium (30 mg/kg, i.p.) and placed in a stereotaxic frame (for rats, Narashige, Japan). Rosenberg et.al's method [Rosenberg G.A. Mun-Bryce S., Mary B.S. and Kornfeld M., Collagenase-induced intracerebral hemorrhage in rats: Stroke, 21, 801-807 (1990)] was followed.
- Mitochondria were isolated as described in example 2.For antioxidant estimations, the mitochondria were rinsed and suspended in phosphate buffer. For the other estimations mitochondria were resuspended in a medium containing sucrose 250 mM, KH 2 PO 4 6 mM and succinate 6mM, pH 7.2. The isolation procedure was carried out at 4 C.
- the oxygen scavenging enzymes, superoxide dismutase (SOD), catalase (CAT) and thiobarbituric acid reactive substances were estimated in mitochondria isolated from forebrain of experimental animals.
- SOD activity was measured by the inhibition of NADH, PMS, NBT and absorbance monitored at 560 nm. Enzyme activity is expressed in U/min/mg protein. [Nishikini M., Rao N.A., Yagi K., The occurrence of superoxide anion in the reaction of reduced PMS and molecular oxygen. Biochem Biophysi. Res. Commun., 46, 849- 854 (1972)].
- CAT activity was assayed by measuring the UV absorbance change of H 2 O 2 at 240 nm according to Aebi [Aebi H., In Methods of Enzymatic Analysis (Third edition) ed. H.U. Bergmeyer Academic Press, New York and London, Vol.2 pp 673-684. (1974)]
- TARS Thiobarbituric acid reactive substance
- Mitochondrial TBARS levels were measured as an index of malondialdehyde and hence lipid peroxidation by the method of Okhawa et. el.[Okhawa H., Ohishi N., Yagi K., Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction: Anal. Biochem., 95, 351 (1979)] at 532 nm. Functional deficit was estimated according to Bederson [Bederson J.B., Pitts, L.H. Tsiji M., Nishimura M.C.
- Mitochondrial protein was determined by the method of Lowry et.al. [Lowry O.H., Rosbrough N.J., Farr. A.L., Randall K.J.; Protein measurement with folin phenol reagent: J. Biol. Chem., 193, 265 (1951)] using bovine serum albumin(BSA) as standard.
- BSA bovine serum albumin
- SOD SOD value in 5 hours was almost normal while in case of test compound (fraction A) given after 7 hours post collagenase treatment the SOD levels were augmented (Fig. 5).
- Catalase This enzyme is reported to be present in minute amount in brain (Fig. 6)
- TBARS At 5 hours post collagenase treatment, the values were close to that of collagenase treated animals, while at 7 hours the values were decreased significantly as compared to the normal group indicating the anti-oxidant property of the test compound-fraction A (Fig.7). Mitochondria were isolated as described in Example 2.
- Fraction A (ar-d-turmerone and turmerones) was given 200 ⁇ l.i.p./300gm.rat in the treated group,while the untreated (control) group received equivalent amount of saline (i.p). Result: The thrombus in the untreated group was 2.8mg. and in the treated group it was
- Rats were made hypertensive according to Goldblatt et. al.[ Goldblatt H., Lynch J., Hanezal R.F., Serville W.W.: Studies on experimental hypertension,: The production of persistent elevation of systolic blood pressure by means of renal ischaemia J Exp Med ;59:347-379 (1934)]. Eight weeks later the hypertensive rats had an average initial blood pressure of 200 mm/Hg. After Curcuma oil , 683.65mg./kg. was administered intraperitoneally the blood pressure fell to 115 mm /Hg in 15 min. and stayed at that level for more than 60 min. Table 1
- the compound lowers the blood pressure significantly in hypertensive rats and not in the normotensive rats. It reduces blood pressure without bradycardia due to ⁇ - adrenergic receptor antagonism or reflex tachycardia common to vasodilator [Nichols A.J,Gallai M.Ruffolo R.P Jr. Studies on the mechanism of arterial vasodilation produced by the noval antihypertensive agent. Carvediolol. Fundani. Clin. Pharmacol., 5:25-38 (1991) ].
- Abdominal aorta was mounted according to Wolfgang et. al. [Wolfgang Auch-Schwelk, Zvonimir S.Karusic and Paul MVanhoutte : contractions to oxygen derived free radicals are augmented in aorta of the spontaneously hypertensive rats., Hypertension ,13, 859- 864(1989)].
- Aortic rings were contracted with norepinephrine 10 "8 to 10 "5 M. The contracted vessels were relaxed by acetylcholine or Curcuma oil, added in a stepwise manner.
- Acetylcholine was added in a concentration of 10 " to 10 " M.
- the final contraction achieved was 0.86 lmg in a 8ml bath (Fig. 8).
- Protein Kinase C activator, Phorbol 12-Myristate 13- Acetate (PMA) (10 "7 M ) induced contraction in the intact and denuded aortic strip preparation.
- PMA Phorbol 12-Myristate 13- Acetate
- Pretreatment with Curcuma oil 0.81 mg. completely inhibited PMA induced contraction. It inhibits protein kinase C [Kaczmarck L.
- Nitric oxide was first characterized in the central nervous system at the intracellular messenger mediating the increase in cGMP levels that follows activation of glutamate receptors (Garthwaite J, Charles S.L. and Chess- Williams R. Endothelium derived relaxing factor release on activation of NMDA receptors suggest a role as intracellular messenger in the brain. Nature 336, 385-388 (1988). Simultaneous generation of NO and superoxide radicals favours the production of a toxic reaction product peroxynitrite anion (Beckman JS, Beckman TW, Chen J, Marshal PA and Freeman BA). Apparent hydroxyl radical production by peroxynitriye: implication for endothelial injury for nitric oxide and superoxide.
- Sodium nitroprusside (SNP) generates Nitric oxide (NO) [Sreejayan and Rao M.N.A: Nitric oxide scavenging by curcuminoids, J.Pharm. Pharmacol., 9,105-107(1997)].
- fraction -A 86.14mg was mixed in phosphate-buffer saline at different concentration of SNP ( 5-40 mM)
- Griess reagent in 1 : 1 ratio was mixed with the test compound (fraction -A).
- results SNP generates nitric oxide and test compound (fraction A) scavenges the nitric oxide thus generated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02781641A EP1453528B1 (en) | 2001-12-14 | 2002-12-14 | Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders |
UA20040705723A UA82057C2 (en) | 2001-12-14 | 2002-12-14 | COMPOSITION basED on AR-D-turmeron and α- anD β-turmeron FOR TREATING NEUROCEREBROVASCULAR DISORDERS |
MXPA04005680A MXPA04005680A (en) | 2001-12-14 | 2002-12-14 | A composition for treating neurocerebrovascular disorders. |
JP2003552313A JP4695839B2 (en) | 2001-12-14 | 2002-12-14 | Composition for treating neurocerebrovascular disorders |
KR1020047009174A KR101001815B1 (en) | 2001-12-14 | 2002-12-14 | A composition for treating neurocerebrovascular disorders |
EEP200400097A EE05374B1 (en) | 2001-12-14 | 2002-12-14 | A composition for the treatment of neurone cerebrovascular devices and a method for the preparation of a rubber contained therein |
AU2002348802A AU2002348802A1 (en) | 2001-12-14 | 2002-12-14 | Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
CA2473874A CA2473874C (en) | 2001-12-14 | 2002-12-14 | A composition for treating neurocerebrovascular disorders |
BR0214962-1A BR0214962A (en) | 2001-12-14 | 2002-12-14 | Composition for treating neurocerebrovascular disorders |
DE60233069T DE60233069D1 (en) | 2001-12-14 | 2002-12-14 | COMPOSITIONS OF CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISEASES |
EA200400807A EA007067B1 (en) | 2001-12-14 | 2002-12-14 | Composition for treating of neurocerebrovascular disorders |
ZA2004/04648A ZA200404648B (en) | 2001-12-14 | 2004-06-11 | A composition for treating neurocerebrovascular disorders |
NO20043000A NO332066B1 (en) | 2001-12-14 | 2004-07-13 | A composition useful for the treatment of neurocerebrovascular diseases, and the use of said composition for the manufacture of a medicament for the treatment of neurocerebrovascular diseases. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34016501P | 2001-12-14 | 2001-12-14 | |
US60/340,165 | 2001-12-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003051380A2 true WO2003051380A2 (en) | 2003-06-26 |
WO2003051380A3 WO2003051380A3 (en) | 2004-06-17 |
Family
ID=23332163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/005366 WO2003051380A2 (en) | 2001-12-14 | 2002-12-14 | Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
Country Status (19)
Country | Link |
---|---|
US (2) | US20060051438A1 (en) |
EP (1) | EP1453528B1 (en) |
JP (1) | JP4695839B2 (en) |
KR (1) | KR101001815B1 (en) |
CN (1) | CN100528149C (en) |
AU (2) | AU2002348802A1 (en) |
BR (1) | BR0214962A (en) |
CA (1) | CA2473874C (en) |
DE (1) | DE60233069D1 (en) |
EA (1) | EA007067B1 (en) |
EE (1) | EE05374B1 (en) |
GE (1) | GEP20084442B (en) |
LT (1) | LT5284B (en) |
LV (1) | LV13250B (en) |
MX (1) | MXPA04005680A (en) |
NO (1) | NO332066B1 (en) |
UA (1) | UA82057C2 (en) |
WO (1) | WO2003051380A2 (en) |
ZA (1) | ZA200404648B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115366A1 (en) * | 2004-05-31 | 2005-12-08 | Kaneka Corporation | Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component |
WO2006118079A1 (en) * | 2005-04-28 | 2006-11-09 | Arata Yamasaki | Antiaging agnet for skin |
WO2012106426A1 (en) | 2011-02-02 | 2012-08-09 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
CN102697757A (en) * | 2012-05-18 | 2012-10-03 | 广州军区广州总医院 | Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy |
WO2012131505A1 (en) * | 2011-03-29 | 2012-10-04 | Council Of Scientific & Industrial Research | Process for the modification of curcuma aromatica essential oil |
WO2013004740A1 (en) | 2011-07-04 | 2013-01-10 | Katholieke Universiteit Leuven | Anticonvulsant activity of turmeric oil and bisabolene sesquiterpenoids |
US9101657B2 (en) | 2009-09-24 | 2015-08-11 | House Foods Corporation | Composition comprising turmeric extract and zedoary extract |
US9775871B2 (en) | 2007-10-03 | 2017-10-03 | Sabell Corporation | Herbal compositions and methods for treating hepatic disorders |
US9796672B2 (en) | 2014-01-31 | 2017-10-24 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
US9815770B2 (en) | 2009-07-31 | 2017-11-14 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
EP1890546B1 (en) * | 2005-05-30 | 2018-11-28 | Benny Antony | Method for improving the bioavailability of curcumin |
US11214540B2 (en) | 2017-05-15 | 2022-01-04 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10543277B2 (en) | 2005-05-30 | 2020-01-28 | Arjuna Natural Private Limited | Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof |
US10286027B2 (en) | 2005-05-30 | 2019-05-14 | Arjuna Natural Extracts, Ltd. | Sustained release formulations of curcuminoids and method of preparation thereof |
US7883728B2 (en) | 2005-05-30 | 2011-02-08 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
US9492402B2 (en) | 2005-05-30 | 2016-11-15 | Benny Antony | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
US8859020B2 (en) | 2005-05-30 | 2014-10-14 | Benny Antony | Treatment of alzheimer's with a curcuminoid mixture and essential oil of turmeric having 45% Ar-turmerone |
JP4980626B2 (en) * | 2006-02-28 | 2012-07-18 | ポーラ化成工業株式会社 | Plasminogen activator inhibitor I inhibitor and food composition comprising the same |
JP5207341B2 (en) * | 2006-10-26 | 2013-06-12 | 独立行政法人産業技術総合研究所 | Inflammatory cytokine production inhibitor |
JP2012519197A (en) * | 2009-03-05 | 2012-08-23 | キージーン・エン・フェー | Plant volatiles based on R-curcumen |
JP5578822B2 (en) * | 2009-09-25 | 2014-08-27 | 株式会社ピカソ美化学研究所 | Acetylcholinesterase inhibitor |
KR101890322B1 (en) * | 2012-01-13 | 2018-08-21 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
JP2014201528A (en) * | 2013-04-02 | 2014-10-27 | クラシエ製薬株式会社 | Antioxidant |
CN106822071B (en) * | 2014-09-23 | 2019-12-27 | 桂林八加一药业股份有限公司 | Chinese medicinal effective component for treating coronary heart disease and hyperlipidemia, its preparation method and method for separating effective component from the same |
CN105738546B (en) * | 2014-12-12 | 2020-01-21 | 桂林八加一药业股份有限公司 | Method for establishing fingerprint of radix curcumae medicinal material and fingerprint thereof |
CN105055449B (en) * | 2015-07-27 | 2019-08-09 | 中国科学院西北高原生物研究所 | A kind of Sailongbone extracts with anti-inflammatory and antalgic activity, preparation method and Chinese materia medica preparation |
CN106491997A (en) * | 2016-12-29 | 2017-03-15 | 王明金 | A kind of Chinese medicine composition of anti-mental disorder and preparation method thereof |
CN106491996A (en) * | 2016-12-29 | 2017-03-15 | 王明金 | A kind of treat Chinese medicine composition of manic disorder and preparation method thereof |
CN106492137A (en) * | 2016-12-29 | 2017-03-15 | 王明金 | A kind of treat Chinese medicine composition of depression and preparation method thereof |
CN106511784A (en) * | 2016-12-29 | 2017-03-22 | 王明金 | Traditional Chinese medicine composition for treating mental diseases and preparation method thereof |
CA3063338A1 (en) * | 2017-05-12 | 2019-12-05 | House Wellness Foods Corporation | Anti-inflammatory composition |
US10391138B2 (en) * | 2017-07-11 | 2019-08-27 | Muniyal Ayurvedic Research Centre | Multidimensional approach for Cancer treatment |
CN108498755B (en) * | 2018-04-17 | 2021-04-09 | 贾洪章 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and its preparation method and application |
JPWO2020004357A1 (en) * | 2018-06-29 | 2021-07-08 | ハウスウェルネスフーズ株式会社 | Compositions for treating, preventing or ameliorating Alzheimer's disease, compositions for suppressing brain nerve cell death, compositions for suppressing microglial activation induced by amyloid β peptide, and PGE2, TNF induced by amyloid β peptide. Composition for suppressing -α or IL-1β production |
CN111617060A (en) * | 2020-05-29 | 2020-09-04 | 广东工业大学 | Application of germacrone |
CN111617059B (en) * | 2020-05-29 | 2023-07-25 | 广东工业大学 | Application of curcuma zedoary diketone |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4842859A (en) * | 1986-09-08 | 1989-06-27 | Yaguang Liu | Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation |
EP0440885A1 (en) * | 1990-02-05 | 1991-08-14 | Pt Darya-Varia Laboratoria | Combinations of compounds isolated from curcuma SPP as anti-inflammatory agents |
WO2001030335A2 (en) * | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
DE10029770A1 (en) * | 2000-06-16 | 2001-12-20 | Transmit Technologietransfer | Treatment of solid tumors, especially brain tumors, using curcumin or derivative to inhibit peritumoral edema and tumor growth and kill the tumor cells |
WO2002074295A1 (en) * | 2001-03-16 | 2002-09-26 | Biosynergen, Inc. | A composition for the prophylaxis or treatment of senile dementia |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU83350A1 (en) | 1981-05-08 | 1983-03-24 | Oreal | COMPOSITION FOR THE TREATMENT OF KERATINIC FIBERS BASED ON CATIONIC POLYMER AND ANIONIC POLYMER HAVING VINYLSULFONIC GROUPS AND METHOD OF TREATING THE SAME |
IN162441B (en) | 1984-12-26 | 1988-05-28 | Council Scient Ind Res | |
US5863938A (en) * | 1991-03-01 | 1999-01-26 | Warner Lambert Company | Antibacterial-wound healing compositions and methods for preparing and using same |
CN1100321A (en) * | 1994-03-27 | 1995-03-22 | 叶启智 | Zibeth and its compound medical injection |
JP2002030081A (en) * | 2000-07-13 | 2002-01-29 | Shiseido Co Ltd | Diaryl heptanoid derivative and matrix metalloprotease activity inhibitor |
-
2002
- 2002-12-14 MX MXPA04005680A patent/MXPA04005680A/en active IP Right Grant
- 2002-12-14 GE GE5642A patent/GEP20084442B/en unknown
- 2002-12-14 UA UA20040705723A patent/UA82057C2/en unknown
- 2002-12-14 KR KR1020047009174A patent/KR101001815B1/en not_active IP Right Cessation
- 2002-12-14 EA EA200400807A patent/EA007067B1/en not_active IP Right Cessation
- 2002-12-14 AU AU2002348802A patent/AU2002348802A1/en not_active Abandoned
- 2002-12-14 EP EP02781641A patent/EP1453528B1/en not_active Expired - Lifetime
- 2002-12-14 WO PCT/IB2002/005366 patent/WO2003051380A2/en active IP Right Grant
- 2002-12-14 BR BR0214962-1A patent/BR0214962A/en not_active IP Right Cessation
- 2002-12-14 DE DE60233069T patent/DE60233069D1/en not_active Expired - Lifetime
- 2002-12-14 CA CA2473874A patent/CA2473874C/en not_active Expired - Fee Related
- 2002-12-14 EE EEP200400097A patent/EE05374B1/en not_active IP Right Cessation
- 2002-12-14 JP JP2003552313A patent/JP4695839B2/en not_active Expired - Fee Related
- 2002-12-14 CN CNB028270770A patent/CN100528149C/en not_active Expired - Fee Related
-
2004
- 2004-06-11 ZA ZA2004/04648A patent/ZA200404648B/en unknown
- 2004-07-02 LT LT2004060A patent/LT5284B/en not_active IP Right Cessation
- 2004-07-13 LV LVP-04-78A patent/LV13250B/en unknown
- 2004-07-13 NO NO20043000A patent/NO332066B1/en not_active IP Right Cessation
-
2005
- 2005-08-24 US US11/210,567 patent/US20060051438A1/en not_active Abandoned
-
2009
- 2009-05-18 US US12/467,383 patent/US20100093870A1/en not_active Abandoned
- 2009-09-07 AU AU2009212969A patent/AU2009212969B2/en not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4842859A (en) * | 1986-09-08 | 1989-06-27 | Yaguang Liu | Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation |
EP0440885A1 (en) * | 1990-02-05 | 1991-08-14 | Pt Darya-Varia Laboratoria | Combinations of compounds isolated from curcuma SPP as anti-inflammatory agents |
WO2001030335A2 (en) * | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
DE10029770A1 (en) * | 2000-06-16 | 2001-12-20 | Transmit Technologietransfer | Treatment of solid tumors, especially brain tumors, using curcumin or derivative to inhibit peritumoral edema and tumor growth and kill the tumor cells |
WO2002074295A1 (en) * | 2001-03-16 | 2002-09-26 | Biosynergen, Inc. | A composition for the prophylaxis or treatment of senile dementia |
Non-Patent Citations (7)
Title |
---|
AMMON H P T ET AL: "PHARMACOLOGY OF CURCUMA LONGA" PLANTA MEDICA, THIEME, STUTTGART, DE, vol. 57, 1991, pages 1-7, XP000916128 ISSN: 0032-0943 * |
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; JAYADEEP, V. R. ET AL: "Changes in the prostaglandin levels in alcohol toxicity: effect of curcumin and N-acetylcysteine" retrieved from STN Database accession no. 134:158763 XP002236053 & JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2000), 11(10), 509-514, * |
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; RAJAKRISHNAN, V. ET AL: "Neuroprotective role of curcumin from Curcuma longa in ethanol-induced brain damage" retrieved from STN Database accession no. 132:246307 XP002236054 & PHYTOTHERAPY RESEARCH (1999), 13(7), 571-574, * |
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAMAMOTO, HISANORI ET AL: "Inhibitory effect of curcumin on mammalian phospholipase D activity" retrieved from STN Database accession no. 128:57137 XP002236055 & FEBS LETTERS (1997), 417(2), 196-198, * |
DATABASE WPI Derwent Publications Ltd., London, GB; AN 1997-245838 XP002236056 & CN 1 100 321 A (YE QIZHI (CN)), 22 March 1995 (1995-03-22) * |
DATABASE WPI Derwent Publications Ltd., London, GB; AN 2002-263510 XP002236057 & JP 2002 030081 A (SHISEIDO CO LTD), 29 January 2002 (2002-01-29) * |
SRIVASTAVA K C: "EXTRACTS FROM TWO FREQUENTLY CONSUMED SPICES - CUMIN (CUMINUM CYMINUM) AND TURMERIC (CURCUMA LONGA) - INHIBIT PLATELET AGGREGATION AND ALTER EICOSANOID BIOSYNTHESIS IN HUMAN BLOOD PLATELETS" PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 37, 1989, pages 57-64, XP000934146 ISSN: 0952-3278 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115366A1 (en) * | 2004-05-31 | 2005-12-08 | Kaneka Corporation | Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component |
WO2006118079A1 (en) * | 2005-04-28 | 2006-11-09 | Arata Yamasaki | Antiaging agnet for skin |
EP1890546B1 (en) * | 2005-05-30 | 2018-11-28 | Benny Antony | Method for improving the bioavailability of curcumin |
US9775871B2 (en) | 2007-10-03 | 2017-10-03 | Sabell Corporation | Herbal compositions and methods for treating hepatic disorders |
US9815770B2 (en) | 2009-07-31 | 2017-11-14 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
US9101657B2 (en) | 2009-09-24 | 2015-08-11 | House Foods Corporation | Composition comprising turmeric extract and zedoary extract |
WO2012106426A1 (en) | 2011-02-02 | 2012-08-09 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
US9499462B2 (en) | 2011-02-02 | 2016-11-22 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
WO2012131505A1 (en) * | 2011-03-29 | 2012-10-04 | Council Of Scientific & Industrial Research | Process for the modification of curcuma aromatica essential oil |
US9068141B2 (en) | 2011-03-29 | 2015-06-30 | Council Of Scientific & Industrial Research | Process for the modification of Curcuma aromatica essential oil |
WO2013004740A1 (en) | 2011-07-04 | 2013-01-10 | Katholieke Universiteit Leuven | Anticonvulsant activity of turmeric oil and bisabolene sesquiterpenoids |
US9782361B2 (en) | 2011-07-04 | 2017-10-10 | Katholieke Universiteit Leuven | Anticonvulsant activity of turmeric oil and bisabolene sesquiterpenoids |
CN102697757B (en) * | 2012-05-18 | 2014-06-04 | 广州军区广州总医院 | Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy |
CN102697757A (en) * | 2012-05-18 | 2012-10-03 | 广州军区广州总医院 | Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy |
US9796672B2 (en) | 2014-01-31 | 2017-10-24 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
US10207991B2 (en) | 2014-01-31 | 2019-02-19 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
US10611728B2 (en) | 2014-01-31 | 2020-04-07 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
US11691947B2 (en) | 2014-01-31 | 2023-07-04 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
US11214540B2 (en) | 2017-05-15 | 2022-01-04 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
US11981636B2 (en) | 2017-05-15 | 2024-05-14 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
Also Published As
Publication number | Publication date |
---|---|
NO20043000L (en) | 2004-07-13 |
EE200400097A (en) | 2004-10-15 |
WO2003051380A3 (en) | 2004-06-17 |
JP4695839B2 (en) | 2011-06-08 |
CN1615144A (en) | 2005-05-11 |
EA007067B1 (en) | 2006-06-30 |
EE05374B1 (en) | 2011-02-15 |
KR101001815B1 (en) | 2010-12-15 |
LT5284B (en) | 2005-11-25 |
CN100528149C (en) | 2009-08-19 |
US20060051438A1 (en) | 2006-03-09 |
MXPA04005680A (en) | 2004-10-15 |
LT2004060A (en) | 2005-06-27 |
EA200400807A1 (en) | 2004-12-30 |
LV13250B (en) | 2006-02-20 |
BR0214962A (en) | 2004-12-14 |
DE60233069D1 (en) | 2009-09-03 |
EP1453528A2 (en) | 2004-09-08 |
EP1453528B1 (en) | 2009-07-22 |
NO332066B1 (en) | 2012-06-18 |
AU2009212969A1 (en) | 2009-10-01 |
AU2009212969B2 (en) | 2011-06-02 |
CA2473874C (en) | 2011-11-22 |
UA82057C2 (en) | 2008-03-11 |
US20100093870A1 (en) | 2010-04-15 |
CA2473874A1 (en) | 2003-06-26 |
JP2005516930A (en) | 2005-06-09 |
KR20040073478A (en) | 2004-08-19 |
GEP20084442B (en) | 2008-08-10 |
ZA200404648B (en) | 2005-11-30 |
AU2002348802A1 (en) | 2003-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009212969B2 (en) | A composition for treating neurocerebrovascular disorders | |
US6991814B2 (en) | Herbal medicaments for the treatment of neurocerebrovascular disorders | |
AU2008289713B2 (en) | Fraction of Melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same | |
JP7490557B2 (en) | Compositions containing berberine | |
KR101285234B1 (en) | Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising Cynanchum Atratum Extracts | |
Yang et al. | A review on α-mangostin as a potential multi-target-directed ligand for Alzheimer's disease | |
AU2021204271A1 (en) | Synergistic composition for osteoarthritis | |
KR100494482B1 (en) | Dendropanax morbifera Lev. extract having a protective effect of hepatic cells, Dendropanax morbifera Lev. fractions, and pharmaceutical composition containing the same | |
JP4863875B2 (en) | Treatment for depression comprising prickly pear plant parts and / or extracts therefrom | |
JP4980626B2 (en) | Plasminogen activator inhibitor I inhibitor and food composition comprising the same | |
KR101782962B1 (en) | Composition for treatment of leukemia and method of manufacturing extract from myrrh | |
Das et al. | Chemometric profiling and anti-arthritic activity of aerial parts of Glinus oppositifolius (L.) Aug. DC. | |
KR20210113203A (en) | Bioactive Phytochemicals in Jujube Trees and Guarana | |
KR20190142672A (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract | |
WO2009141645A1 (en) | Cancer therapy | |
KR102069125B1 (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract | |
Maurya et al. | PHYTOCHEMICAL AND PHARMACOLOGICAL INVESTIGATION OF OCIMUM SANCTUM MEDICINAL PLANTS FOR THE TREATMENT OF HEPATOTOXICITY | |
US20240148705A1 (en) | Pharmaceutical composition | |
JPH02286622A (en) | Anti-inflammatory agent | |
Eskandary et al. | Effects of garlic and nimodipine on cerebral blood flow and their neuroprotective effects after brain ischemia in rabbit | |
KR20150105154A (en) | The pharmaceutical composition comprising extract of opuntia ficus-indica for the treatment or prevention of garstric disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2473874 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/04648 Country of ref document: ZA Ref document number: PA/a/2004/005680 Country of ref document: MX Ref document number: 200404648 Country of ref document: ZA Ref document number: 2002348802 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047009174 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003552313 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002781641 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004060 Country of ref document: LT |
|
ENP | Entry into the national phase |
Ref document number: 2004 20040078 Country of ref document: LV Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028270770 Country of ref document: CN Ref document number: 1200400654 Country of ref document: VN Ref document number: 200400807 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20040275 Country of ref document: UZ Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5642 Country of ref document: GE Ref document number: 8296 Country of ref document: GE |
|
WWP | Wipo information: published in national office |
Ref document number: 2002781641 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2838/DELNP/2004 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004060 Country of ref document: LT |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004060 Country of ref document: LT |